

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)



(10) International Publication Number
WO 2021/222544 A1

- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61P 35/00* (2006.01)
- (21) **International Application Number:**
PCT/US2021/029866
- (22) **International Filing Date:**
29 April 2021 (29.04.2021)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/019,068 01 May 2020 (01.05.2020) US
63/122,848 08 December 2020 (08.12.2020) US
- (71) **Applicant: NGM BIOPHARMACEUTICALS, INC.**
[US/US]; 333 Oyster Point Boulevard, South San Francisco, California 94080 (US).
- (72) **Inventors: DUEY, Dana Yen Mei;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **EBENS, JR., Allen James;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **KAPLAN, Daniel David;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **LAM, Chia-Ying Kao;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **MONDAL, Kalyani;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US).

STONE, Geoffrey William; 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **WANG, Yan;** 333 Oyster Point Boulevard, South San Francisco, California 94080 (US).


(74) **Agent: GHAI, Kanika et al.;** FISH & RICHARDSON, P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) **Title: ILT-BINDING AGENTS AND METHODS OF USE THEREOF**

Figure 22



(57) **Abstract:** The present disclosure provides binding agents, such as antibodies, that specifically bind ILT2, ILT4, or both ILT2 and ILT4, as well as compositions comprising the binding agents, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising the binding agents.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*